Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial Post author: Post published:December 10, 2024 Post category:uncategorized A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). You Might Also Like Study reveals common yet overlooked mystical experiences impact well-being May 26, 2024 Combination immunotherapy yields 10-year survival for metastatic melanoma patients September 16, 2024 Measles misinformation is on the rise — and Americans are hearing it, survey finds April 23, 2025
Combination immunotherapy yields 10-year survival for metastatic melanoma patients September 16, 2024